Telitacicept Demonstrates Durable Preservation of Kidney Function Through Two Years in Phase 3 TELIGAN Trial in IgA Nephropathy
Globe Newswire•22/10/2026•16:05 ET
0
Key Highlights
- ➤eGFR slope -0.6 versus -5.7 mL/min/1.73 m²/year for placebo at 104 weeks
- ➤Telitacicept cut confirmed ≥30% eGFR decline risk by 89% versus placebo
- ➤Week 104 proteinuria fell 60.3% from baseline versus 0.9% increase for placebo
- ➤No telitacicept patients reached composite kidney failure endpoint versus five on placebo
- ➤China granted telitacicept conditional approval for IgA nephropathy in June 2026
Expert Statements
Jean-Paul Kress, Chairman and Chief Executive Officer of Vor Bio
“At 104 weeks, TELIGAN demonstrated a substantial reduction in proteinuria and important evidence of durable kidney protection”
Jean-Paul Kress, Chairman and Chief Executive Officer of Vor Bio
“An annualized eGFR slope approaching zero, lower rates of kidney function deterioration, and sustained proteinuria reductions following the transition to every-other-week dosing together reinforce the clinical potential of telitacicept.”
Jean-Paul Kress, Chairman and Chief Executive Officer of Vor Bio
“These findings add to the growing body of evidence supporting dual BAFF/APRIL inhibition as we continue to advance our global Phase 3 programs in myasthenia gravis and Sjögren’s disease.”
Annualized eGFR slope of -0.6 vs. -5.7 mL/min/1.73 m²/year for placebo, a 5.1 mL/min/1.73 m²/year treatment difference (p<0.001)
89% and 81% reductions in risk of confirmed ≥30% and ≥40% eGFR declines, respectively
Get started
Create a free account to read the full story.